Aquestive Therapeutics, Inc. (AQST)
- Previous Close
3.9000 - Open
3.9300 - Bid 3.9100 x 700
- Ask 3.9400 x 700
- Day's Range
3.7750 - 4.0100 - 52 Week Range
1.2500 - 6.2300 - Volume
1,913,600 - Avg. Volume
2,570,745 - Market Cap (intraday)
353.574M - Beta (5Y Monthly) 2.91
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1300 - Earnings Date May 7, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.00
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
www.aquestive.com135
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AQST
Performance Overview: AQST
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AQST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AQST
Valuation Measures
Market Cap
353.57M
Enterprise Value
363.02M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.76
Price/Book (mrq)
--
Enterprise Value/Revenue
7.18
Enterprise Value/EBITDA
307.12
Financial Highlights
Profitability and Income Statement
Profit Margin
-15.56%
Return on Assets (ttm)
-16.49%
Return on Equity (ttm)
--
Revenue (ttm)
50.58M
Net Income Avi to Common (ttm)
-7.87M
Diluted EPS (ttm)
-0.1300
Balance Sheet and Cash Flow
Total Cash (mrq)
23.87M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-16.22M